Pay in 4 interest-free payments of $6.40 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
If youre not seeing results at 7.5mg after 8 weeks, a review can determine whether to increase to 10mg or investigate other factors
The SUSTAIN-6 cardiovascular outcomes trial established that semaglutide also reduces the risk of major adverse cardiovascular events (MACE) by 26% relative to placebo in high-risk patients a finding that fundamentally changed the treatment landscape for metabolic disease
For obesity therapy, GLP-1 RAs primarily exert their effects through appetite suppression and delayed gastric emptying, leading to reduced caloric intake and sustained weight loss
Trial #1 85% of participants reached an A1c of 7% and lost up to 7.8 kg (17.16 lbs) A1C is a test that measures a persons average blood glucose level over the past 2 to 3 months
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight (NCT04881760)
